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ABSTRACT 
 
MYH9-related disease (MYH9-RD) is a rare autosomal-dominant disorder caused by mutations in the gene 
for non-muscle myosin heavy chain IIA (NMMHC-IIA). MYH9-RD is characterized by a considerable 
variability in clinical evolution: patients present at birth with only thrombocytopenia, but some of them 
subsequently develop sensorineural deafness, cataract, and/or nephropathy often leading to end-stage renal 
disease (ESRD). We searched for genotype-phenotype correlations in the largest series of consecutive 
MYH9-RD patients collected so far (255 cases from 121 families). Association of genotypes with non-
congenital features was assessed by a generalized linear regression model. The analysis defined disease 
evolution associated to seven different MYH9 genotypes that are responsible for 85% of MYH9-RD cases. 
Mutations hitting residue R702 demonstrated a complete penetrance for early-onset ESRD and deafness. The 
p.D1424H substitution associated with high risk of developing all the non-congenital manifestations of 
disease. Mutations hitting a distinct hydrophobic seam in the NMMHC-IIA head domain or substitutions at 
R1165 associated with high risk of deafness but low risk of nephropathy or cataract. Patients with p.E1841K, 
p.D1424N and C-terminal deletions had low risk of non-congenital defects. These findings are essential to 
SDWLHQWV¶FOLQLFDOPDnagement and genetic counseling and are discussed in view of molecular pathogenesis of 
MYH9-RD.  
 
Key Words: MYH9-related disease, non-muscle myosin, inherited thrombocytopenia, genetic nephropathy, 
genetic deafness.  
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INTRODUCTION 
 
MYH9-related disease (MYH9-RD) is an autosomal-dominant disorder caused by mutations in MYH9 
(OMIM 160775), the gene for the heavy chain of non-muscle myosin IIA (NMMHC-IIA) [Kelley et al., 
2000; Seri et al., 2000; Kunishima et al., 2001]. MYH9-RD patients present at birth with thrombocytopenia 
and platelet macrocytosis. The degree of thrombocytopenia is greatly variable among different subjects and 
the reduced platelet count can associate with mild to severe bleeding tendency. Most MYH9-RD patients 
develop, during infancy or adult life, additional clinical manifestations: sensorineural deafness, presenile 
cataract, and/or proteinuric nephropathy, which usually evolves into kidney failure and often leads to end-
stage renal disease (ESRD). Each of these non-congenital manifestations can occur alone or can variably 
associate with the other ones. Therefore, clinical evolution of MYH9-RD is extremely variable: in some 
patients, a mild, asymptomatic thrombocytopenia remains the only manifestation of the disease throughout 
life, while other subjects develop over time complex syndromic pictures characterized by spontaneous 
bleedings, ESRD, deafness and/or cataract [Balduini et al., 2011; Kunishima and Saito, 2010]. MYH9-RD 
encompasses four syndromes that have been considered for many years as distinct disorders, May-Hegglin 
Anomaly (MHA, MIM 155100), Sebastian syndrome (SBS, MIM 605249), Fechtner syndrome (FTNS, MIM 
153640), and Epstein syndrome (EPTS, MIM 153650). After the discovery of MYH9 as the gene responsible 
for all of these syndromes, analyses of wide case series of patients demonstrated that MHA, SBS, FTNS and 
EPTS actually represented some of the different possible clinical presentations of the same condition, for 
which the definition of MYH9-RD, or MYH9 disorder, has been introduced [Seri et al., 2003; Heath et al., 
2001; Arrondel et al., 2002; Althaus and Greinacher, 2009; Kunishima and Saito, 2010; Balduini et al., 
2011].  
 
Non-muscle myosin-IIA is a cytoplasmic myosin expressed in most cell types and tissues that participates in 
several key processes requiring generation of chemomechanical forces by the cytoskeleton, such as cell 
motility, cytokinesis, cell polarization and maintenance of cell shape [Vicente-Manzanares et al., 2009]. Like 
all conventional myosins, it presents a hexameric structure formed by a NMMHC-IIA dimer and two pairs of 
light chains. Each NMMHC-IIA molecule comprises three anatomically distinct domains: the N-terminal 
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globular head domain (HD), the light chain binding lever arm or neck, and the C-terminal tail domain (TD) 
[Eddinger and Meer, 2007] (Supp. Figure S1, B). The three-dimensional structure of the globular HD 
consists of four subdomains connected by flexible linkers: the N-terminal SH3-like motif, the upper and the 
lower 50kDa subdomains, and the converter subdomain [Sellers, 2000] (Supp. Figure S2). The so-called 
motor domain includes the highly-conserved functional regions essential for production of chemomechanical 
force, such as the actin-binding cleft, the ATP-binding pocket, the relay loop, and the short SH1 helix 
[Dominguez et al.,1998; Sweeney and Houdusse, 2010; Baumketner, 2012]. The TD comprises two regions: 
a long alpha-helical coiled-coil, which connects two NMMHC-IIA moieties to form one dimer and 
represents the binding site of different dimers to form functional myosin filaments, and a 37-residue C-
terminal non-helical tailpiece (NHT), which is a phosphorylation site with regulatory functions [Eddinger 
and Meer, 2007; Sanborn et al., 2011] (Supp. Figure S1).  
 
The spectrum of mutations identified so far in MYH9-RD is limited, suggesting that only specific alterations 
of NMMHC-IIA cause the disease. In most patients, MYH9-RD is due to missense mutations affecting either 
the HD or the coiled-coil region of the TD. Missense mutations hit only 21 of the 1960 NMMHC-IIA 
residues [Balduini et al., 2011; De Rocco et al., 2013]. In other patients, MYH9-RD derives from nonsense or 
frameshift alterations of the last exon (exon 41) resulting in deletion of a variable portion of the NHT. In rare 
cases, the causative mutation is an in-frame deletion or duplication removing or adding short amino acid 
sequences, mainly within the C-terminal part of the coiled-coil. In about 80% of the families, the mutations 
affected six residues: S96 or R702 located in the HD, R1165, D1424 or E1841 in the coiled-coil, or R1933 in 
the NHT [Balduini et al., 2011].  
 
Due to the large variability of the clinical picture, the search for genotype-phenotype correlations in MYH9-
RD has been an important research topic since the identification of this disorder [Seri et al., 2003; Althaus 
and Greinacher, 2009; Kunishima and Saito, 2010]. In 2005, Dong and colleagues suggested a relationship 
between mutations of some NMMHC-IIA residues and the phenotypes of the respective families [Dong et 
al., 2005]. In 2008, the analysis of 108 patients enrolled in the Italian registry for MYH9-RD showed that the 
mutations affecting the HD of NMMHC-IIA were associated with a higher incidence of nephropathy and 
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deafness and with more severe thrombocytopenia than mutations hitting the TD [Pecci et al., 2008a]. Some 
of the reports on very small case series published afterwards were consistent with this model based on HD 
vs. TD contraposition [Pecci et al., 2010; Sekine et al., 2010; Han et al., 2011], while others suggested the 
need for a more articulate prognostic model [De Rocco et al., 2009; Jang et al., 2012].  
 
After the first genotype-phenotype study published in 2008, the number of patients enrolled in the Italian 
registry rose from 108 to 255 and the observation time increased by more than 5 years. The analysis of this 
very large case series showed that different mutations within the same NMMHC-IIA domain, and even 
hitting the same residue, can have different effects on phenotype, thus allowing us to define a novel and 
more accurate prognostic model.    
 
PATIENTS AND METHODS 
 
Patients 
 
This study included all the consecutive patients enrolled in the Italian Registry for MYH9-RD 
(www.registromyh9.org) at the date of March 2012. Supp. Figure S3 describes in detail the protocol used 
IRUSDWLHQWV¶HQUROOPHQWPatients having the inclusion criteria were recruited at the different centers 
participating in the registry network. All patients or their legal guardians provided written informed consent. 
The study was approved by the Institutional Review Board of the IRCCS Policlinico San Matteo Foundation, 
Pavia, Italy.  
 
Immunofluorescence assay  
 
Immunofluorescence assay for the search for NMMHC-IIA leukocyte inclusions on the peripheral blood 
smears was performed in all the consecutive unrelated probands with inclusion criteria (Supp. Figure S3). 
This assay was used as a screening test on the basis of the previous evidences indicating that it represents the 
most sensitive method to identify patients with MYH9-RD [Savoia et al., 2010; Althaus and Greinacher, 
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2010; Kunishima et al., 2003; Kunishima and Saito, 2010]. In particular, the assay demonstrated a 100% 
sensitivity for the identification of subjects with MYH9 mutations [Savoia et al., 2010]. The 
immunofluorescence assay was centralized at the laboratory of the Department of Internal Medicine, IRCCS 
Policlinico San Matteo Foundation, Pavia.  The test was performed using the anti-NMMHC-IIA mouse 
monoclonal antibody NMG2 according to a previously reported protocol [Savoia et al., 2010].  
 
Mutational screening of MYH9 
 
Mutational screening of MYH9 was centralized at the laboratories of Institute for Maternal and Child Health, 
IRCCS "Burlo Garofolo", Trieste, Italy or of the 0HGLFDO*HQHWLFV8QLW3ROLFOLQLFR6DQW¶2UVROD-Malpighi, 
University of Bologna, Bologna, Italy. The analysis was performed using a tiered approach based on 
localization and frequency of mutations so far detected [Savoia et al., 2010]. First, we took into consideration 
exons 2, 17, 31, 39, and 41. If no mutation was identified, screening was extended to exons 11, 21, 25, 26, 
27, 32, 33, 35, and 38. In some patients, the analysis was extended to all the MYH9 coding exons. The coding 
exons and the respective exon-intron boundaries were amplified by PCR as described [Savoia et al., 2010]. 
PCR products were sequenced using an ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction 
Kit and an ABI 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Nucleotide numbering 
reflects the MYH9 cDNA with +1 corresponding to the A of the ATG translation initiation codon in the 
reference sequence (RefSeq NM_002473.4). Therefore, the initiation codon is codon 1. All the mutations are 
enlisted in a locus specific mutation database (http://www.LOVD.nl/MYH9) at the Leiden Open Variation 
Database. 
 
Phenotype assessment 
 
Patients were studied at diagnosis and then reevaluated at least once a year. PDWLHQWV¶DJHXVHGIRUWKH
analysis was that at the time of the last clinical evaluation. The phenotype of the already reported patients 
was updated for this study. Proteinuric nephropathy was recorded when quantitative 24-hours proteinuria 
was more than 0.5 gr in at least two consecutive examinations repeated with an interval of three months. 
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Chronic renal failure (CRF) was recorded in patients with proteinuric nephropathy for values of serum 
creatinine at least 1.5-fold higher than the upper reference value or an estimated GRF < 60 mL/min/1.73 m3 
according to the CKD-EPI creatinine equation [Levey et al., 2009], in at least two consecutive examinations. 
ESRD was defined by the need for continuous dialysis. The presence of sensorineural hearing loss was 
defined on the basis of the results of audiometric examination. Deafness was recorded for a bone threshold 
average greater than 25 dB at 1000, 2000 and 4000 Hz. For infants the hearing function was examined by 
sensory evoked potentials. Presenile cataract was searched for by ophthalmological evaluation. In most 
cases, the automated or microscopic platelet count was repeated more than once, and the mean value was 
recorded. The above investigations were performed in all the enrolled patients independently of the presence 
of a symptomatic disease.  
Severity of spontaneous bleeding was evaluated according to the World Health Organization (WHO) 
bleeding score: grade 0, no bleeding; grade 1, only cutaneous bleeding; grade 2, mild blood loss; grade 3, 
gross blood loss, requiring transfusion; grade 4, debilitating blood loss, retinal or cerebral associated with 
fatality. The history of spontaneous bleeding based on WKHSDWLHQWV¶entire lifetimes. Provoked bleeding 
episodes were not considered for this study.  
 
Statistical analysis 
 
Data were described as mean and standard deviation (SD) and as counts and percent for continuous and 
categorical variables, respectively. The association of genotype and phenotype was assessed by means of a 
generalized linear regression model. The association of the genotype with the clinical outcome during 
follow-up was evaluated with event-free survival analysis (log-rank test & Cox model). Rate per 100 person 
year and their 95% confidence intervals (95%CI) were computed, while accounting for familial aggregation. 
Given the lack of independence of the members of the same families, we adopted the appropriate control for 
this: for all regression models, Huber-White robust standard errors were computed to account for intra-
familial aggregation of data. Observation started at birth. Stata 12.1 (Stata Corp, College Station, TX, USA) 
was used for computation. A 2-sided p-value<0.05 was considered statistically significant. Post-hoc 
comparisons need to be interpreted with caution in the framework of multiple tests. Within each phenotype, 
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tests were performed hierarchically with the increase of the genetical detail and subsequent p values were 
considered at their face 5% value only if the preceding test was significant at the 5% level. Moreover, 
Bonferroni correction was applied for all multiple and post-hoc comparisons.  
 
RESULTS 
 
Enrollment and mutational screening 
 
A total of 255 consecutive patients belonging to 121 unrelated MYH9-RD pedigrees were enrolled. Patients 
were 134 males and 121 females, and their mean age was 33 years (SD 21). Mutational screening of MYH9 
allowed us to identify 34 different mutations (Table 1). All the variations have been already described as 
causative of the MYH9-RD [Balduini et al., 2011; De Rocco et al., 2013].  
In 34 families (28%) mutations affected the HD of NMMHC-IIA. They were missense variations resulting in 
single amino acid substitutions that were mainly located in two specific regions of the globular head (Supp. 
Figure S2). In 24 families (20% of all families) mutations affected the R702 residue located in the short SH1 
helix of the lower 50kDa subdomain [Eddinger and Meer, 2007]. Nine families had mutations of exon 2 
hitting residues W33 or V34 of the SH3-like motif, or residues N93, A95 or S96 of the upper 50kDa 
subdomain [Sellers, 2000]. By investigation of a three-dimensional model of the human NMMHC-IIA head, 
it was previously demonstrated that all these five residues are clustered together to form a distinct 
hydrophobic interface between the SH3-like motif and the motor domain [Dominguez et al., 1998; Kahr et 
al., 2009]. Thus, we referred to these substitutions as mutations of the SH3-like motif/motor domain 
(SH3/MD) interface. The p.R718W identified in one family was located in the converter subdomain and 
therefore was the only HD mutation outside the SH1 helix or the SH3/MD interface.  
In 87 families (72%) mutations affected the TD. In most cases (n=54, 45%), they were single residue 
substitutions located in the coiled-coil region. Consistent with data from literature, three residues were most 
frequently affected: R1165, D1424, and E1841 (8%, 16%, and 12% of families and 9%, 21%, and 13% of 
patients, respectively) (in bold in Table 1). In 28 families (23%), we identified nonsense or frameshift 
alterations of exon 41 resulting in deletion of a variable portion of the NHT. The most frequent NHT 
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alteration was the p.R1933* (20 families, 16%, and 44 patients, 17%). Finally, in rare cases (5 families), we 
found in-frame deletions or duplications resulting in in-frame alterations affecting the N-terminal part of the 
coiled-coil (Table 1). The spectrum of mutations identified in our case series was very similar, and, 
therefore, representative of that of the whole of MYH9-RD families reported so far [Balduini et al., 2011].  
 
Genotype-phenotype correlations  
 
To search for genotype-phenotype correlations, we performed four different and complementary analyses. (i) 
First, we grouped patients according to the NMMHC-IIA domain hit by mutations (HD vs. TD), in order to 
confirm the previous findings [Pecci et al., 2008a]. (ii) Second, we grouped patients according to the specific 
region of the protein hit by mutations: the substitutions in the SH1 helix (corresponding to R702 
substitutions) were compared with the substitutions in the SH3/MD interface, the substitutions in the coiled-
coil region, and the deletions hitting the NHT. The in-frame deletions or duplications in the coiled-coil were 
excluded from this analysis because of their rarity and to make the coiled-coil group more homogeneous. (iii) 
A third analysis was carried out by clustering patients according to the residue of NMMHC-IIA hit by 
mutations, and by comparing the five groups with at least 10 evaluable patients: residue R702 vs. R1165 vs. 
D1424 vs. E1841 vs. R1933 (in bold in Table 1). (iv) Finally, we considered the possibility that substitution 
of the same residue with different amino acids could have different effects on phenotype. By taking into 
account only the mutations with at least 10 evaluable patients, the p.R702C substitution was compared with 
the p.R702H, and the p.D1424H was compared with the p.D1424N (Table 1).   
 
The phenotype of investigated patients is reported in detail in Supp. Tables S1 and S2. To search for 
genotype-phenotype correlations, each manifestation of the MYH9-RD was analyzed separately.  
 
Nephropathy. Sixty-one of 247 evaluable patients (25%) developed the proteinuric nephropathy (mean age 
of evaluable cases, 33 years). The mean age at onset of nephropathy was 27 years (SD 14), and 72% of 
patients were diagnosed before the age of 35. Nephropathy occurred in 44 of 118 pedigrees (37%). This 
picture resulted in an overall rate per 100 person year of 0.77 (95%CI 0.56-1.08).  
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The results of genotype-phenotype analyses are detailed in Table 2. The comparison between the two 
NMMHC-IIA domains confirmed that mutations in the HD are associated with higher incidence of 
nephropathy than TD mutations (p<0.001). However, the analysis according to the different regions of 
NMMHC-IIA hit by mutations disclosed a remarkably different effect of mutations in the two affected 
regions of the HD. In fact, substitutions in the SH1 helix were associated with a much higher risk of 
nephropathy than substitutions in the SH3/MD interface (Table 2; HR 11.3, 95%CI 2.2-58.2, p<0.001) 
(Figure 1). The risk deriving from SH3/MD interface substitutions was similar to that globally associated 
with substitutions in the coiled-coil of the TD, while the deletions at NHT correlated with a significantly 
lower incidence of kidney damage (Table 2 and Figure 1). The event-free survival analysis showed that all 
patients with SH1 helix (R702) substitutions are expected to develop kidney damage before the age of 45 
years (Figure 1). The analysis according to the five most frequently affected residues confirmed the more 
severe consequences of the R702 substitutions and the lower risk associated with the deletions at R1933 
compared to mutations at each of the three investigated coiled-coil residues (R1165, D1424 or E1841, Table 
2). Moreover, the further analyses suggested that different coiled-coil substitutions could have different 
effects. In particular, the prognostic significance of the D1424 mutations greatly differed according to the 
amino acid replacing the aspartic acid. In fact, while the p.D1424H mutation was associated with a notable 
risk of nephropathy (Table 2), none of the 13 patients with the p.D1424N developed this complication 
(p=0.005 in the comparison with D1424H).  
 
Figure 2 shows the results of the exploratory post-hoc analysis comparing the incidence of kidney damage 
associated with 7 distinct genotypes. These included the substitutions at the two affected regions of the HD 
and at the three more frequently hit residues of the coiled-coil. NHT deletions were included as a unique 
group, as our analysis showed no different prognostic significance among these deletions. Accordingly, 
similar results were obtained by considering the NHT deletions or deletions at R1933 alone (data not shown). 
On the contrary, the p.D1424H and the p.D1424N were included as distinct genotypes on the basis of their 
clearly different prognostic behavior. In summary, the R702 substitutions had the most severe effects. 
Among the other mutations, the p.D1424H was identified as being associated with a relatively high-risk 
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profile. Post-hoc analysis showed that the incidence of nephropathy associated with the p.D1424H was 
significantly higher than that of the E1841 substitution or the NHT deletions, with a statistical trend with 
respect to the SH3/MD interface or R1165 substitutions, most likely due to the low number of observations 
in the latter groups. Finally, the substitutions at the SH3/MD interface, R1165 or E1841 appeared associated 
with a low incidence of nephropathy, and the risk of this complication was almost negligible for the NHT 
deletions and the p.D1424N (Figure 2). 
 
Evolution of nephropathy. We then investigated whether, after the onset of the proteinuric nephropathy, the 
progression of kidney damage to CRF and ESRD was different in patients with different genotypes. After a 
median follow-up of 36 months (range 1-228), 40 of the 61 patients with nephropathy (66%) developed 
CRF. The mean age at onset of CRF was 31 years (SD 15). Twenty-six patients (43%) also developed ESRD 
(median follow-up, 39 months, range 1-540) at a mean age of 30 years (SD 17). The overall rate per 100 
person year for the progression to ESRD was 6.79 (95%CI 4.32-9.53).  
We compared the progression of kidney damage between patients with SH1 helix (R702) and those with 
coiled-coil substitutions, since in the other genotype groups only few patients had nephropathy (two patients 
for SH3/MD interface substitutions and three for NHT deletions, respectively). Table 3 and Figure 3 show 
the significantly more severe evolution for patients with SH1 helix (R702) mutations. Of note, the most 
remarkable difference between the two groups was observed for progression to ESRD, while only a slight, 
albeit significant, difference was observed for progression to CRF (Table 3). Finally, no differences in 
progression to CRF or ESRD were observed among patients with different substitutions within the coiled-
coil (D1424, R1165, or E1841).   
 
The picture shown in Figure 3 suggest that, whereas in patients with R702 substitution this MYH9 mutation 
is the only determinant of ESRD, in subjects with coiled-coil substitutions additional genetic or 
environmental factors are required for the progression to ESRD. The screening of all the MYH9 coding exons 
was performed in the 9 patients with coiled-coil mutations who developed ESRD, in order to test whether an 
additional MYH9 mutation could explain their more severe evolution. We found that one patient with the 
p.D1424H carried also an in trans p.K910Q substitution inherited from the mother (Seri et al., 2003). As the 
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SDWLHQW¶VPRWKHUKDVQRVLJQVRIMYH9-RD at clinical and laboratory evaluation, the p.K910Q is likely to be 
a non-pathogenetic variant, even if an effect in addition to that of the p.D1424H cannot be definitely 
excluded. In the remaining 8 patients, no additional MYH9 mutations was found. On the whole, these results 
indicate that the severe evolution of nephropathy in these patients is not ascribable to additional MYH9 
mutations.   
 
Sensorineural deafness. Sensorineural deafness was present in 114 of 237 patients who underwent 
audiometric examination (48%) and in 67 of 116 pedigrees (58%). Ninety percent of patients with altered 
audiometric examination had a clinically relevant hearing loss. The mean age at onset was 31 years (SD 19). 
The ages at onset were homogeneously distributed from the first to the sixth decade, as 36% of patients 
developed the hearing defect before 20 years of age, 33% between 20 and 40, and 31% after 40. The 
resulting overall rate per 100 person year was 1.71 (95%CI 1.39-2.11).  
 
Genotype-phenotype correlations for sensorineural deafness are detailed in Table 4. As with nephropathy, 
the SH1 helix substitutions were associated with the highest risk (p<0.001), while the deletions in the NHT 
correlated with a significantly lower risk compared with mutations in the other NMMHC-IIA regions 
(p0.001). The subsequent analyses (according to residues and mutations) disclosed the different prognostic 
significance of the different substitutions within the coiled-coil. In fact, the D1424 and the R1165 changes 
were associated with higher risk of deafness than the E1841 substitution. Moreover, as with nephropathy, the 
p.D1424N was associated with a particularly low incidence of hearing impairment, which was significantly 
lower than that deriving from the p.D1424H (p<0.001, Table 4).  
 
In summary, our analyses allowed us to assess the risk of deafness associated with the 7 genotypes identified 
above and defined three distinct prognostic groups (Figure 4). Patients with SH1 helix (R702) mutations 
presented higher risk than all the other genotypes: the event-free survival analysis showed that all of these 
patients are expected to develop the hearing defect before 40 years of age. Patients with SH3/MD interface, 
p.D1424H and R1165 substitutions presented an intermediate-high risk of developing deafness, whereas the 
p.D1424N or p.E1841K substitutions and the NHT deletions were associated with the lowest incidence 
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(Figure 4). The post-hoc analysis confirmed the consistency of the definition of these three prognostic 
groups. In fact, the risk associated with a given genotype was significantly different from that of each 
genotype assigned to a different prognostic group, while it did not significantly differ from that of the 
genotypes assigned to the same prognostic group (data not shown).  
 
Cataract. Cataract was observed in 43 of 235 evaluable patients (18%), thus represented the less frequent 
extra-hematological manifestation of MYH9-RD. In most cases (n=31, 72%) it was bilateral. The mean age at 
onset was 37 years (SD 30) and 4 patients had congenital forms. The overall rate per 100 person year was 
0.57 (95%CI 0.41-0.82).  
Confirming previous observations [Pecci et al., 2008a], we found that the incidence of cataract was not 
different between HD and TD mutations (Table 5). The main finding from the more in-depth analyses was 
that patients with the NHT deletions have a lower risk of developing cataract than those with substitutions in 
the coiled-coil or SH1 helix. Consistently, patients with deletions at R1933 presented lower risk than patient 
with D1424 or R702 substitutions (Table 5). Of note, the highest incidence of cataract was recorded for the 
p.D1424H substitution, even if further data are needed to confirm the more deleterious effect of this mutation 
compared  to the other genotypes (Table 5).  
 
Thrombocytopenia and bleeding diathesis. In MYH9-RD, the routine automated platelet counting 
overestimates the severity of thrombocytopenia, as cell counters fail to recognize the very large platelets of 
these patients. The actual platelet count (PLTC) can be assessed only by counting upon phase-contrast 
microscopy [Balduini et al., 2011]. In our case series, the median PLTC measured by cell counters in all the 
255 patients was 31 x109/L (IQR 16-53). Microscopic PLTC was available for 167 patients, and the median 
value was 70 x109/L (IQR 40-95). In the same patient population, the median automated PLTC was 26 
x109/L (IQR 13-46). Of note, the microscopic PLTC was within the normal range (153 to 182 x109/L) in 6 
patients (4%). 
Supplementary Table 1 summarizes genotype-phenotype correlations for PLTC as assessed by microscopic 
counting. In brief, patients with HD mutations had more severe thrombocytopenia with respect to those with 
TD mutations (p<0.001). Statistical significance was reached also when each of the HD genotypes was 
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compared with each of the TD genotypes. In contrast, no significant differences were observed among the 
different genotypes within the same NMMHC-IIA domain (Supp. Table S3). Similar results were obtained 
when the automated PLTCs of all the 255 patients were considered (data not shown).  
 
Evaluation of spontaneous bleeding tendency by the WHO bleeding scale was available for 183 patients. 
Most cases had no bleeding (105 patients, 57%) or WHO grade 1 bleeding (27 patients, 15%). Thirty-five 
patients (19%) presented grade 2 bleeding and 16 (9%) had grade 3. The bleeding score strongly correlated 
with PLTCs, as measured by microscopy or cell counters (p<0.001 in both cases) (Supp. Figure S4). The 
patients with grade 3 bleeding had a median microscopic PLTC of 38 x109/L (IQR 25-55) and an automated 
count of 10 x109/L (median, IQR 5-17). Consistent with these observations, the genotype-phenotype 
correlations for bleeding diathesis showed a picture very similar to that observed for PLTC (Supp. Table S4).  
 
DISCUSSION 
 
The vast majority of MYH9-RD patients at birth have only platelet macrocytosis and a variable degree of 
thrombocytopenia; however, their clinical evolution is very different depending on the occurrence of the 
non-congenital manifestations of the disease. Thus, predicting the natural history of MYH9-RD is particularly 
iPSRUWDQWIRUSDWLHQWV¶management and genetic counseling. By the systematic analysis of the largest case 
series ever reported, we demonstrated that MYH9 genotype is a major determinant of the disease phenotype, 
and we defined the disease evolution associated with 7 genotypes that, on the whole, account for about 85% 
of the MYH9-RD cases [Balduini et al., 2011]. These findings are recapitulated in Table 6.  
 
The R702 substitutions are associated with the most severe phenotype. The R702 patients present with 
severe thrombocytopenia (median PLTC in our case series, 27 x109/L) and all of them are expected to 
develop the proteinuric nephropathy and deafness by the fourth decade (Figures 2 and 4). Moreover, their 
nephropathy evolves aggressively, with a median time to progression to ESRD of about 5 years from onset 
of proteinuria (Figure 3). By investigating 30 patients (23 families), we observed almost no variability in 
their clinical course, demonstrating that the R702 genotype has an almost complete penetrance for severe 
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thrombocytopenia plus early and aggressive nephropathy and deafness. Some drugs, such as ACE-inhibitors 
or angiotensin receptor blockers, were suggested to be effective in reducing MYH9-RD proteinuria and 
slowing down progression of kidney damage [Pecci et al., 2008b]. The follow-up for occurrence of 
proteinuria should therefore be particularly close for R702 patients, in order to start treatment as early as 
possible. Whereas the severe consequences of R702 mutations have been suggested by earlier observations 
[Pecci et al., 2008a; Han et al., 2010; Sekine et al., 2010], the present study provided several novel genotype-
phenotype correlations. Three results seem particularly relevant. (i) The p.D1424H substitution can be 
distinguished from all the other non-R702 mutations by a relative and absolute high risk to develop the non-
congenital manifestations of the disease. Most of the p.D1424H patients are expected to have developed 
proteinuria by the sixth decade of life (Figure 2), and all of them are predicted to develop deafness before 
the age of 60 (Figure 4); moreover, the p.D1424H results in a higher probability of cataract occurrence 
compared to all the other analyzed genotypes except R702 mutations (Table 4). Thus, in a hierarchical 
prognostic model, p.D1424H is the genotype associated with the highest risk of a syndromic disease after the 
R702 mutations. Interestingly, the substitution of the same aspartic acid with asparagine is much less 
deleterious, since it associated with a significantly lower incidence of all the non-congenital features of the 
disease. (ii) Except for the mutations at R702, most of the HD mutations reported so far hit residues that are 
clustered to form a distinct hydrophobic seam at the SH3/MD interface [Kahr et al., 2009; Balduini et al., 
2011]. These mutations associated with a less severe phenotype than the R702 substitutions. These results 
contradict the conclusions from our previous, smaller genotype-phenotype study, which concluded that all 
patients with HD mutations share the same severe prognosis [Pecci et al., 2008a]. Instead, the SH3/MD 
substitutions associate with an ³auditory´ phenotype: all these patients are expected to develop sensorineural 
deafness before 60 years of age (Figure 4), while the risk of developing nephropathy and cataract is low 
(Figure 2 and Table 5). The same auditory phenotype is linked to the substitutions at R1165 (Table 6). (iii) 
Finally, the p.D1424N and p.E1841K substitutions, as well as the mutations hitting the NHT, correlated with 
a low incidence of the non-congenital complications, and therefore with a high probability that 
thrombocytopenia remains the only manifestation of the MYH9-RD throughout life. In particular, the risk 
profile deriving from the NHT deletions and from the p.D1424N was found to be particularly low.  
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The different evolution of proteinuric nephropathy between patients with R702 mutations and those with 
coiled-coil substitutions is another relevant aspect from a clinical point of view. In fact, while proteinuria is 
expected to rapidly evolve to ESRD in nearly all patients with R702 mutations, less than half of patients with 
coiled-coil mutations and proteinuria will progress to ESRD (Figure 3). Considering only patients with 
ESRD, the median age at onset of ESRD was 24 years (SD 9) for R702 and 42 years (SD 23) for coiled-coil 
mutations, respectively. Therefore, even if certain subjects with coiled-coil mutations frequently develop 
kidney damage (as with the p.D1424H patients), their defect is less progressive. This picture suggests that, 
whereas for R702 patients the MYH9 mutation is the only determinant of ESRD development, for patients 
with coiled-coil substitutions additional genetic or environmental factors interact with the MYH9 mutation to 
determine progression to ESRD. The absence of additional MYH9 mutations in the patients with coiled-coil 
substitutions who developed ESRD suggests that variants in other genes interacting with MYH9 represent the 
additional genetic factors for their more severe evolution.  
 
It is important to underline that this study was aimed at investigating the clinical evolution of the typical 
MYH9-RD, which is defined by congenital macrothrombocytopenia and NMMHC-IIA leukocyte inclusions, 
and represents the markedly most frequent known phenotype deriving from MYH9 mutations. However, the 
p.R705H mutation of NMMHC-IIA was reported as responsible for DFNA17, a non-syndromic form of 
deafness, in two unrelated pedigrees [Lalwani et al., 2000]. Patients having further possible phenotypes not 
including thrombocytopenia or leukocyte NMMHC-IIA inclusions would be missed by the protocol used for 
recruitment to this study. Future investigation is required to explore the possibility that some MYH9 
variations could result in further syndromic or non-syndromic phenotypes other than MYH9-RD or DFNA17.  
 
It is generally accepted that the more severe consequences of the HD vs. TD mutations derive from the fact 
that the HD mutants impair the NMM-IIA ATPase activity, while the TD alterations impact molecule 
assembly but do not affect ATPase activity [Balduini et al., 2011]. However, the present study identified 
some relevant exceptions to this scheme based on simple HD vs. TD contraposition, as the R702 mutations 
have worse effects than the SH3/MD substitutions, and the TD p.D1424H mutation showed the most 
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deleterious effect among the non-R702 alterations. This suggests that, at least for some mutants, additional 
pathogenetic mechanisms are involved in alteration of NMM-IIA function.  
 
Consideration of the molecular interactions within the myosin head allows us to propose a testable 
hypothesis for the basis of the differences between MD/SH3 interface and R702 mutations. Hu and 
colleagues reported that both the p.N93K (in the SH3/MD interface) and the p.R702C (SH1 helix) greatly 
reduce the ATPase activity of NMM-IIA, and that the extent of the reduction was even greater for the 
p.N93K [Hu et al., 2002]. Thus, it seems hard to explain the more severe consequences on phenotype of the 
R702 compared to the SH3/MD substitutions just on the basis of defective ATPase activity. However, by 
homology with known crystal structures of other myosin IIs, the R702 interacts directly with the relay loop 
near D503, which is the vital conduit between ATP hydrolysis and the position of the converter and thus of 
the lever swing [Dominguez et al., 1998; Bauer et al., 2000; Gourinath et al., 2003; Risal et al., 2004]. In 
particular, R702 stabilizes the link between the SH1 helix and the relay loop by its long paraffin chain 
contributing to the hydrophobic seam between these two key regions and also likely forming a salt bridge 
with the D507 in the loop. Mutation to the shorter side chains of cysteine, histidine, or serine with their 
reduced hydrophobic character will weaken the seam and disrupt the salt bridge. By consequence, the 
coupling between the motor and converter domains will be weakened, thus uncoupling ATPase activity from 
force production. In contrast, mutations in the SH3/MD interface, as the linkage to the relay loop is indirect, 
have the potential to affect ATPase activity through different routes, including an overall destabilisation of 
HD folding. Consistent with this, Hu and colleagues reported greater aggregation in vitro of the N93K than 
for the R702C [Hu et al., 2002]. Thus, a hypothesis for the greater severity of R702 mutations than SH3/MD 
interface mutations in MYH9-RD is that the former could be defective in both ATPase activity and holding 
tension whereas the latter has low ATPase but could maintain tension.  
 
Possible molecular mechanisms for the impact of D1424 mutations are worthy of discussion because this can 
suggest why different mutations at this residue can have very different impacts, and can further suggest 
future biophysical experiments on expressed proteins. In general, the mechanism of TD point mutations will 
depend on the position of the residue within the heptad repeat motif (abcdefg) of amino acid residues that is 
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the building block of the coiled-coil tail (Suppl. Figure S1, D) [Franke et al., 2005]. Any given TD mutant 
could either enhance or reduce any or all of: (i) coiled-coil stability, (ii) filament nucleation and assembly, 
(iii) folding of the molecule into the 10S inactive conformation (Supp. Figure S1, A-C). Indeed, this third 
alternative has not been considered in previous work, but could be germane because in 10S the tail is folded 
into three roughly equal and closely apposed segments that wrap around one of the heads [Burgess et al., 
2007]. D1424 occupies a heptad c position in the NMMHC-IIA tail. Mutation is thus unlikely to perturb the 
helical stability or interactions between the two chains of the molecule (the hydrophobic seam here is well 
populated by hydrophobic residues and therefore stable). The p.D1424H is a negative to positive charge 
change and is thus expected to alter ionic interactions more than p.D1424N, which is a negative to 
polar/uncharged change. The charge change in p.D1424H could have a destabilizing impact on packing of 
molecules into functional filaments by weakening interactions with positive-charged zones of adjacent 
molecules. However, we propose that an additional impact might be on the stability of the 10S, inactive 
FRQIRUPHU,QIDFW'¶VSRVLWion in the tail, about 88 nm from the heads, corresponds to where the 
second segment of the folded tail contacts the motor domain, close to the converter subdomain in a region of 
net positive surface charge (Supp. Figure S1, A) [Burgess et al., 2007; Jung et al., 2008]. Since this compact 
conformer is sensitive to salt, the stabilizing interactions are likely ionic, so the negative to positive charge 
change in p.D1424H could be much more destabilizing than the p.D1424N, causing the molecules to unfold. 
NMMHC-IIA unfolding would favor filament formation, and thus might make this mutant more sensitive to 
activation and prolong activity following dephosphorylation of the regulatory light chains. Perturbations of 
monomer-polymer equilibria could underlie the increased association of mutant NMM-IIA with the actin 
cytoskeleton that was experimentally observed in MYH9-RD platelets [Canobbio et al., 2005]. Interestingly, 
the R1165 mutations, which are also associated with a significant incidence of extra-hematological 
manifestations, are also located in a potentially critical region for the stability of the 10S conformer. 
Measurements of the lengths of the three segments of the tail in smooth muscle myosin suggest that the first 
sharp bend of the 10S conformer is at residue 1175, which would be S1163 in NMMHC-IIA (Supp. Figure 
S1, A) [Eddinger and Meer, 2007]. The R1165 may therefore be a part of this bend, or if it just follows the 
bend could be interacting with the adjacent first segment of folded tail, and mutations could destabilize the 
10S soluble shutdown state.  
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In conclusion, this study identified novel genotype-phenotype correlations that allow us to predict the clinical 
evolution of MYH9-RD in about 85% of patients. 7KHVHGDWDDUHHVVHQWLDOIRUSDWLHQWV¶FOLQical management 
and genetic counseling, but are also useful for the elucidation of molecular pathogenesis of the disease.  
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FIGURE LEGENDS  
 
Figure 1. Occurrence of nephropathy according to the region of NMMHC-IIA affected by mutation. 
The association of genotype with the occurrence of nephropathy was assessed over time by means of event-
IUHHVXUYLYDODQDO\VLV3DWLHQW¶VDJHZDVXVHGWRPHDVXUHWLPH7KHIROORZ-up was stopped at the age of 
diagnosis of nephropathy or at the last phenotype evaluation in the case of censoring. Only p values < 0.05 
are reported. After Bonferroni correction, significance for p < 0.008.  
 
Figure 2. Evolution of nephropathy to ESRD in patients with SH1 helix (R702)substitutions or coiled-
coil substitutions. The follow-up was initiated at the time of diagnosis of nephropathy and stopped at the 
time of diagnosis of ESRD or at the last phenotype evaluation in the case of censoring.  
 
Figure 3. Occurrence of nephropathy in patients with different MYH9 mutations.  The figure shows the 
results of the post-hoc statistical comparison between 7 different MYH9 genotypes. Genotypes were 
identified by comparing patients with mutations in four different regions of the NMMHC-IIA, then patients 
with mutations at the five most frequently hit residues of these regions. A further analysis compared the 
patients with p.R702C with those with the p.R702H, and the patients with p.D1424H with those carrying the 
p.D1424N. On the whole, the characterized genotypes are responsible for about 85% of the reported MYH9-
RD cases. Only p values  0.05 are reported. After Bonferroni correction, significance for p  0.002 for all 
the new comparisons. 1 = significance for p  0.008 and 2 = significance for p   0.005 after Bonferroni 
correction (see notes to Table 2).    
 
Figure 4. Occurrence of sensorineural deafness in patients with different MYH9 mutations. Figure 
shows the results of the post-hoc statistical comparison between 7 different genotypes. Only p values  0.05 
are reported. After Bonferroni correction, significance for p IRUDOO the new comparisons. 1 = 
significance for p DQG2 = significance for p DIWHU%RQIHUURQLFRUUHFWLRQVHHQRWHVWR7DEOH
4).    
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Supporting Figure S1. Schematic representation of non-muscle myosin IIA (NMM-IIA) domain 
structure, folding and assembly. (A): Diagram of the folded, shut-down 10S conformation of NMM-IIA 
based on the structure of smooth muscle myosin as seen by negative stain EM (adapted from Burgess et al. 
2007). The tail folds into three segments of approximately equal length (numbered 1, 2 and 3). The amino 
acid residue numbers for the bends are derived assuming homology with smooth muscle myosin. The 
position of D1424 is indicated (red dot) on tail segment 2: it lies adjacent to the converter subdomain 
(yellow) of the left head. The R1165 (green dot) is located in a region where the tail forms a sharp bend 
between segment 1 and 2 in the 10S conformation. Phosphorylation of the regulatory light chain (RLC) 
causes unfolding of NMM-IIA into the 6S conformation. (B): Domain structure of 6S NMM-IIA. The 
essential light chain (ELC; green) and RLC (orange) bind to the lever arm region of the heavy chain. Two 
NMM-IIA heavy chains dimerise through their long, C-WHUPLQDOĮ-helices to form a coiled-coil tail with a 
non-helical tail piece at the C-terminus starting at G1924. (C): Interactions between the tails of 6S NMM-IIA 
molecules yield bipolar filaments that function to draw together actin filaments of opposite polarity. (D) 
Heptad plot showing hydrophobic and ionic interactions in the coiled-coil. The sequence is plotted as a 
helical wheel in which each helix is modified to 3.5 residues per turn such that two turns coincide with one 
KHSWDGUHSHDW7KHUHVXOWLQJSDLUHGVWUXFWXUHLVYLHZHGDORQJWKHKHOL[D[LV+\GURSKRELFUHVLGXHVLQWKHµD¶
DQGµG¶SRVLWLRQVFDQHVFDSHLQWHUDFWLRQZLWKDTXHRXVVROXWLRQE\IRUPLQJDK\GURSKRELF seam when the two 
SRO\SHSWLGHFKDLQVDVVRFLDWHWRJHWKHUVROLGDUURZV7KHµJ¶DQGµH¶UHVLGXHVDUHRIWHQFKDUJHGDQGFDQPDNH
LRQLFµJ¶WRµH¶LQWHUDFWLRQVVKRZQE\WKHGRWWHGDUURZVDFURVVWKHVHDPZKLFKVWDELOL]HVWKHFRLOHG-coil.  
 
Supporting Figure S2. Schematic representation of the three-dimensional structure of the NMMHC-
IIA head domain (HD). The globular head includes four subdomains: from the N- to the C-terminus, they 
are the SH3-like motif, the upper and the lower 50kDa subdomains, and the converter subdomain. The two 
50 kDa subdomains form the so-called motor domain, as it contains the functional regions essential for 
production of chemomechanical forces. The converter domain connects the lever arm that amplifies the 
movement produced by conformational changes of the motor domain. In our case series, the HD mutations 
were mostly located in two specific regions of the head: a distinct hydrophobic interface between the N-
terminal SH3 motif and the 50kDa upper subdomain (SH3/MD interface, blue dot) (Kahr et al., 2009; 
25 
 
Dominguez et al. 1998) and at R702 (red dot) localized in the SH1 helix (yellow) of the 50kDa lower 
subdomain. The relay loop is also schematically represented (see text). 
 
Supporting Figure S3. Enrollment to this genotype-phenotype study. Patients having the inclusion 
criteria were identified at the different centers participating in the network of the Italian registry for MYH9-
RD, whereas the immunofluorescence assay for NMMHC-IIA and molecular screening of MYH9 were 
centralized, as detailed in the text.  
 
Supporting Figure S4. Correlation between microscopic platelet count and WHO bleeding score. For 
each WHO bleeding grade, median platelet count (midline), 25th-75th percentiles (box) and extremes 
(whiskers) are shown.  




Table 1. Results of mutational screening in 255 MYH9-RD patients (121 families). 
 
     
N. of patients 
(n. of families) 
Exon 
Nucleotide 
change 
NMMHC-IIA 
domain 
NMMHC-IIA 
region 
Amino acid 
change 
Total 
enrolled 
Previously 
reported 
Ref. 
2 c.99G>T HD SH3/MD i p.W33C 1 (1)  1 (1) A 
2 c.101T>G HD SH3/MD i p.V34G 3 (1) 3 (1) D 
2 c.279C>G HD SH3/MD i p.N93K 1 (1) 1 (1)  B 
2 c.284C>A HD SH3/MD i p.A95D 3 (1) 1 (1) G 
2 c.287C>T HD SH3/MD i p.S96L 6 (5) 3 (3)  B,G 
17 c.2104C>T HD SH1 helix   p.R702C 19 (17) 15 (14) B,G 
17 c.2104C>A HD SH1 helix  p.R702S  1 (1) 1(1)  D  
17 c.2105G>A  HD SH1 helix   p.R702H 11 (6) 7(4) B,G 
17 c.2152C>T HD Converter p.R718W 1 (1) 1 (1)  B 
21 
 c.2539 
_2559dup 
TD Coiled-coil 
p.M847_ 
E853dup 
2 (1) 2 (1) D 
25 
c.3142 
_3162del  
TD Coiled-coil 
p.K1048_ 
E1054del 
2 (1) 2 (1) D 
25 
c.3195 
_3215del 
TD Coiled-coil 
p.E1066_ 
A1072del 
3 (2)  1 (1) B 
25 
c.3195 
_3215dup 
TD Coiled-coil 
p.E1066_ 
A1072dup 
3 (1) 3 (1) G 
26 c.3463A>G TD Coiled-coil p.T1155A 1 (1) 1 (1) G 
26 c.3464C>T TD Coiled-coil p.T1155I 4 (1) 2 (1) B 
26 c.3485G>C TD Coiled-coil p.R1162T 3 (2) 3 (2) c 
27 c.3493C>T TD Coiled-coil p.R1165C 18 (8) 8 (3) B 
27 c.3494G>T TD Coiled-coil p.R1165L 5 (2) 1 (1) G 
31 c.4270G>C TD Coiled-coil p.D1424H 33 (9) 20 (5) B,G 
31 c.4270G>A TD Coiled-coil p.D1424N 13 (8) 7 (6) B,G 
31 c.4270G>T TD Coiled-coil p.D1424Y 7 (3) 2 (2) B,G 
31 c.4339G>T TD Coiled-coil p.D1447Y 1 (1) 1 (1) D 
31 c.4340A>T TD Coiled-coil p.D1447V 5 (2) 4 (1) B 
32 c.4546G>A TD Coiled-coil p.V1516M 3 (1) 2 (1) E 
33 c.4670G>T TD Coiled-coil p.R1557L 2 (1) 2 (1) E 
39 c.5521G>A TD Coiled-coil p.E1841K 34 (15) 24 (11) B,G 
41 
c.5770 
_5779del 
TD NHT 
 
p.G1924Rfs*21 
 
3 (1) 3 (1) E 
41 c.5773delG TD NHT 
 
p.D1925Tfs*23 
 
5 (1) 4 (1) B 
41 c.5788delG TD NHT 
 
p.V1930Cfs*18 
 
4 (1) 1 (1) E 
41 c.5797C>T TD NHT 
 
p.R1933* 
 
44 (20) 20 (13) B,G 
41 c.5797delC TD NHT 
 
p.R1933Efs*15 
 
2 (1) 2 (1) B 
41 c.5800delA TD NHT 
 
p.M1934Wfs*14 
 
2 (1) 2 (1) F 
41 c.5821delG TD NHT 
 
p.D1941Mfs*7 
 
5 (2) 5 (2) B 
41 c.5833G>T TD NHT 
 
p.E1945* 
 
5 (1) 3 (1) B 
 
Notes: the five residues most frequently affected by mutations (see text) are evidenced in bold.  
Nucleotide numbering reflects the MYH9 cDNA with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence (RefSeq NM_002473.4). The initiation codon is codon 1. All the 
mutations are enlisted in a locus specific mutation database (http://www.LOVD.nl/MYH9) at the Leiden 
Open Variation Database. 
Abbreviations:  HD = Head Domain; TD = Tail Domain; SH3/MD i = SH3-like motif/motor domain interface; 
NHT = Non-Helical Tailpiece. Ref.= reference. 
 
 References: A = Kahr et al., 2009 (reference listed in the text). B = Pecci et al., 2008a (reference listed in the 
text). C = Vettore S et al., Eur J Med Genet 2010; 53: 256-60. D = De Rocco D et al., 2013 (reference listed in 
the text). E = Pecci A et al., 2010 (reference listed in the text). F = Savoia A et al., Ann Hematol 2010; 
89:1057-9. G = Savoia A et al., 2010 (reference listed in the text). 
 
Table 2 - Correlations between genotype and incidence of nephropathy in 247 MYH9-RD patients.  
 
 
 
N. of 
patients 
(families) 
 
Affected 
patients, 
% 
Mean age 
at onset, 
years (SD) 
Rate per 100 person 
year (95% CI) 
 
p values 
 
NMMHC-IIA  
domain 
    
 
Head 45 (33) 26 (58%) 20 (10) 2.73  (1.63-4.41) p<0.001 
Tail 202 (85) 35 (17%) 32 (15) 0.52  (0.33-0.86)  
      
NMMHC-IIA  
region 
    
p<0.001 
SH3/MD interface 14 (9) 2  (14%) 35 (1) 0.52  (0.10-4.02)  
SH1 helix (R702) 30 (23) 23 (77%) 19 (10) 4.35  (3.29-5.65) p<0.001 vs. all other groups 1 
Coiled-coil  123 (53) 31 (25%) 31 (15) 0.75  (0.47-1.27)  
NHT  69 (27) 3  (4%) 37 (21) 0.12  (0.02-1.72) p<0.001 vs. coiled-coil, p<0.05 vs. SH3/MD interface 1 
      
NMMHC-IIA  
residue 
    
p<0.001 
R 702  30 (23) 23 (77%) 19 (10) 4.35  (3.29-5.65) p<0.001 vs. all other groups 2 
R 1165  21 (10) 4 (19%) 21 (7) 0.57  (0.08-1.10)  
D 1424 51 (20) 18 (35%) 32 (14) 1.18  (0.67-2.31) p=0.01 vs. E1841 2 
E 1841 33 (14) 6 (18%) 37 (17) 0.46  (0.20-1.30)  
R 1933 45 (20) 1 (2%) 60 (ne) 0.06  (0.02-0.07) p<0.001 vs. D1424, p=0.01 vs. R1165, p<0.05 vs. E1841 2 
      
R702 substitutions      
p.R702C 18 (9) 16 (89%) 16 (8) 5.74  (4.40-7.42) p=0.05 2 
p.R702H 11 (8) 6 (55%) 21 (8) 3.08  (1.92-4.72)  
      
D1424 substitutions      
p.D1424H 33 (16) 16 (48) 31 (14) 1.74 (0.90-3.43) p=0.005 2 
p.D1424N 13 (6) 0 (0) ne 0  
Notes: only p ǀĂůƵĞƐч ? ? ? ?ĂƌĞƌĞƉŽƌƚĞĚ ?1 сƉч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ?2 сƉч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ?
Abbreviations: ne = not evaluable.  
 
  
Table 3. Progression of nephropathy to chronic renal failure (CRF) and end-stage renal disease (ESRD) in 54 MYH9-RD patients according to the NMMHC-IIA 
region affected by mutation.  
 
 CRF ESRD 
NMMHC-IIA 
region 
(n. of patients) 
Affected patients 
(%) 
[median follow-up, 
mo.] 
Rate per 100 
person year 
(95%CI) 
p value 
Affected patients 
(%) 
[median follow-up, 
mo.] 
Rate per 100 
person year 
(95%CI) 
p value 
 
SH1 helix (R702) 
(n=23) 
 
17  (74%) 
[48] 
19.76  
(13.8-28.6) 
p=0.02 
14 (61%) 
[48] 
18.33 
(12.43-27.20) 
p=0.001 
 
Coiled-coil 
(n=31) 
 
19  (61%) 
[36] 
8.72 
(6.04-12.49) 
 
9 (29%) 
[40] 
3.35 
(1.55-7.96) 
 
 
Abbreviation: mo.= months.  
 
Additional information: 
For the mutations in SH1 helix, the age at onset of nephropathy, IRC and ESRD was 19 (SD 9), 23 (16) and 24 (9) years, respectively.  
For the mutations in the coiled-coil, the age at onset of nephropathy, IRC and ESRD was 31 (SD 15) 38 (8) and 42 (23) years, respectively.    
 
 
 
 
 
 
 
 
 
 
 
Table 4 - Correlations between genotype and incidence of sensorineural deafness in 237 MYH9-RD patients.  
 
 
 
N. of 
patients 
(families) 
 
Affected 
patients,  
n (%) 
Mean age 
at onset, 
years (SD) 
Rate per 100 person 
year (95% CI) 
 
p values 
 
NMMHC-IIA  
domain 
    
 
Head 44 (34) 36 (82%) 17 (13) 5.47  (3.93-1.73) p<0.001 
Tail 193 (83) 78 (40%) 37 (17) 1.31  (1.01-0.86)  
      
NMMHC-IIA  
region 
    
p<0.001 
SH3/MD interface 14 (9)  9  (64%) 28 (16) 3.17  (1.76-5.74) p=0.01 vs. coiled-coil 1 
SH1 helix (R702) 29 (23) 27 (93%) 13 (9) 7.76  (5.96-9.93) p<0.001 vs. all other groups 1 
Coiled-coil  118 (50) 61 (52%) 34 (16) 1.71  (1.30-2.31)  
NHT  65 (28) 15 (23%) 53 (17) 0.71  (0.47-1.11) pч0.001 vs. all other groups 1 
      
NMMHC-IIA  
residue 
    
p<0.001 
R 702  29 (23) 27 (93%) 13 (9) 7.76  (5.96-9.93) p<0.001 vs. all other groups 2 
R 1165  19 (9) 10 (53%) 26 (13) 2.34  (1.17-5.61)   
D 1424 50 (19) 33 (66%) 31 (15) 2.37  (1.85-3.18)  
E 1841 30 (14) 13 (43%) 45 (14) 1.10  (0.64-2.05) p<0.001 vs. R1165 and D1424 2 
R 1933 42 (21) 9 (21%) 54 (11) 0.67  (0.40-1.20) p<0.001 vs. R1165 and D1424 2 
      
R702 substitutions       
p.R702C 18 (17) 17 (94%) 11 (6) 9.09 (6.68-12.12)  
p.R702H 10 (6)  9  (90%) 16 (11) 6.04 (3.88-9.20)  
      
D1424 substitutions      
p.D1424H 32 (9) 25 (78%) 32 (16) 2.73 (2.35-3.20) p<0.001 2 
p.D1424N 11 (7) 1  (9%) 50 (ne) 0.31 (0.10-0.38)  
Notes: only p ǀĂůƵĞƐч ? ? ? ?ĂƌĞƌĞƉŽƌƚĞĚ ?1 сƉч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ?2 сƉч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ?
Abbreviations: ne = not evaluable.  
 
Table 5 - Correlations between genotype and incidence of cataract in 235 MYH9-RD patients.  
 
 
 
N. of 
patients 
(families) 
 
Affected 
patients, 
% 
Mean age 
at onset, 
years (SD) 
Rate per 100 person 
year (95% CI) 
 
p values 
 
NMMHC-IIA  
domain 
    
 
Head 42 (33) 6 (14%) 33 (16) 0.57  (0.28-1.32)  
Tail 193 (83) 37 (19%) 38 (21) 0.57  (0.39-0.86)  
      
NMMHC-IIA  
region 
    
p=0.002 
SH3/MD interface 13 (8) 2 (15%) 52  (6) 0.49  (0.15-2.44)  
SH1 helix (R702) 28 (24) 4 (14%) 23  (3) 0.64  (0.25-2.07)  
Coiled-coil  119 (51) 31 (26%)  38 (20) 0.77  (0.52-1.18)  
NHT  64 (26) 3 (5%)  57 (20) 0.13  (0.05-0.52) p<0.001 vs. coiled-coil; p=0.001 vs. SH1 helix 1 
      
NMMHC-IIA  
residue 
    
p<0.001 
R 702  28 (24) 4 (14%)      23 (3) 0.64  (0.25-2.07)  
R 1165  22 (10) 4 (18%) 45 (23) 0.55  (0.28-1.22)  
D 1424 47 (19) 17 (36%) 32 (18) 1.18  (0.74-2.17) p<0.05 vs. E1841 2 
E 1841 31 (13) 7 (23%) 50 (11) 0.57  (0.27-1.53)  
R 1933 40 (19) 1 (2%) 75 (ne) 0.07  (0.02-0.06) p<0.005 vs. R702, p<0.001 vs. D1424,  
p<0.05 vs. R1165 and E1841 2 
      
R702 substitutions      
p.R702C 18 (17) 4 (22%) 23 (3) 1.06 (0.44-3.17)  
p.R702H 9 (6) 0  ne 0.00  
      
D1424 substitutions      
p.D1424H 29 (10) 13 (45%) 28 (17) 1.60 (1.18-2.39) p=0.01 2 
p.D1424N 12 (8) 0  ne 0.00  
Notes: only p ǀĂůƵĞƐч ? ? ? ?ĂƌĞƌĞƉŽƌƚĞĚ ?1 сƉч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ?2 сƉч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ? 
Abbreviations: ne = not evaluable.  
Table 6. Summary of the risk of occurrence of extra-hematological manifestations of MYH9-RD according to 
seven MYH9 genotypes.  
 
 
 
Nephropathy 
 
Deafness Cataracts 
 
SH3/MD interface 
substitutions 
 
Low risk 
Before age 60 years in 
all patients 
Low risk 
R702 substitutions 
Before age 40 years in 
all patients 
Progression to ESRD in 
all patients 
Before age 40 years in 
all patients 
Low risk 
 
R1165 substitutions 
 
Low risk 
Before age 60 years in 
all patients 
Low risk 
p.D1424H 
High risk 
Progression to ESRD in a 
minority of patients 
Before age 60 years in 
all patients 
Probably higher risk 
 
p.D1424N 
 
Very low risk Low risk Low risk 
 
p.E1841K 
 
Low risk Low risk Low risk 
 
NHT deletions 
 
Very low risk Low risk Very low risk 
 
  
 
 
 
Supporting Figure S1. Schematic representation of non-muscle myosin IIA (NMM-IIA) domain 
structure, folding and assembly. (A): Diagram of the folded, shut-down 10S conformation of NMM-IIA 
based on the structure of smooth muscle myosin as seen by negative stain EM (adapted from Burgess et al. 
2007). The tail folds into three segments of approximately equal length (numbered 1, 2 and 3). The amino 
acid residue numbers for the bends are derived assuming homology with smooth muscle myosin. The 
position of D1424 is indicated (red dot) on tail segment 2: it lies adjacent to the converter subdomain 
(yellow) of the left head. The R1165 (green dot) is located in a region where the tail forms a sharp bend 
between segment 1 and 2 in the 10S conformation. Phosphorylation of the regulatory light chain (RLC) 
causes unfolding of NMM-IIA into the 6S conformation. (B): Domain structure of 6S NMM-IIA. The 
essential light chain (ELC; green) and RLC (orange) bind to the lever arm region of the heavy chain. Two 
NMM-IIA heavy chains dimerise through their long, C-WHUPLQDOĮ-helices to form a coiled-coil tail with a 
non-helical tail piece at the C-terminus starting at G1924. (C): Interactions between the tails of 6S NMM-IIA 
molecules yield bipolar filaments that function to draw together actin filaments of opposite polarity. (D) 
Heptad plot showing hydrophobic and ionic interactions in the coiled-coil. The sequence is plotted as a 
helical wheel in which each helix is modified to 3.5 residues per turn such that two turns coincide with one 
KHSWDGUHSHDW7KHUHVXOWLQJSDLUHGVWUXFWXUHLVYLHZHGDORQJWKHKHOL[D[LV+\GURSKRELFUHVLGXHVLQWKHµD¶
DQGµG¶SRVLWLRQVFDQHVFDSHLQWHUDFWLRQZLWKDTXHRXVVROXWLRQE\IRUPLQJDK\GURSKRELFVHDPZKHQWKHWZR
polypeptide chains associaWHWRJHWKHUVROLGDUURZV7KHµJ¶DQGµH¶UHVLGXHVDUHRIWHQFKDUJHGDQGFDQPDNH
LRQLFµJ¶WRµH¶LQWHUDFWLRQVVKRZQE\WKHGRWWHGDUURZVDFURVVWKHVHDPZKLFKVWDELOL]HVWKHFRLOHG-coil.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting Figure S2. Schematic representation of the three-dimensional structure of the NMMHC-
IIA head domain (HD). The globular head includes four subdomains: from the N- to the C-terminus, they 
are the SH3-like motif, the upper and the lower 50kDa subdomains, and the converter subdomain. The two 
50 kDa subdomains form the so-called motor domain, as it contains the functional regions essential for 
production of chemomechanical forces. The converter domain connects the lever arm that amplifies the  
movement produced by conformational changes of the motor domain. In our case series, the HD mutations 
were mostly located in two specific regions of the head: a distinct hydrophobic interface between the N-
terminal SH3 motif and the 50kDa upper subdomain (SH3/MD interface, blue dot) (Kahr et al., 2009; 
Dominguez et al. 1998) and at R702 (red dot) localized in the SH1 helix (yellow) of the 50kDa lower 
subdomain. The relay loop is also schematically represented (see text). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           
Supporting Figure S3 
 
 
Supporting Figure S3. Enrollment to this genotype-phenotype study. Patients having the inclusion 
criteria were identified at the different centers participating in the network of the Italian registry for MYH9-
RD, whereas the immunofluorescence assay for NMMHC-IIA and molecular screening of MYH9 were 
centralized, as detailed in the text.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting Figure S4 
 
 
 
 
 
Supporting Figure S4. Correlation between microscopic platelet count and WHO bleeding score. For each WHO bleeding grade, median platelet count 
(midline), 25th-75th percentiles (box) and extremes (whiskers) are shown.  
Supporting Table S1. Occurrence of the extra-hematological complications of the MYH9-RD in 255 patients 
belonging to 121 families.  
 
 
Family 
 
MYH9 mutation 
N. of  
patients 
 
Mean age  
[years] 
(range) 
 
 
N. of affected/evaluable patients   
 
Nephropathy ESRD Deafness Cataract 
1 p.W33C 1 14 0 0 1/1   0 
2 p.V34G 3 40 (11-58) 0/3 0/3 2/3   1/3  
3 p.N93K 1 46 1/1  0/1 1/1   0/1 
4 p.A95D 3 47 (32-75) 0/3 0/3 3/3 0/3 
5 p.S96L 1 7 0/1 0/1 0/1 0/1 
6 p.S96L 1 4 0/1 0/1 0/1 0/1 
7 p.S96L 1 9 0/1 0/1 0/1 0/1 
8 p.S96L 2 33 (16-50) 1/2 0/2 2/2 1/2 
9 p.S96L 1 4 0/1 0/1 0/1 0/0 
10 p.R702C 1 8 1/1 0/1 1/1 0/1 
11 p.R702C 1 35 1/1 1/1 1/1 0/1 
12 p.R702C 2 29 (27-32) 2/2 1/2 2/2 1/1 
13 p.R702C 2 26 (12-40) 1/2 0/1 2/2 0/2 
14 p.R702C 1 22 1/1 0/1 1/1 0/1 
15 p.R702C 1 21 1/1 1/1 1/1 0/1 
16 p.R702C 1 24 1/1 1/1 1/1 1/1 
17 p.R702C 1 18 1/1 0/1 1/1 0/1 
18 p.R702C 1 22 1/1 1/1 1/1 0/1 
19 p.R702C 1 43 1/1 1/1 1/1 0/1 
20 p.R702C 1 21 1/1 0/1 1/1 0/1 
21 p.R702C 1 4 0/1 0/1 0/1 0/1 
22 p.R702C 1 6 1/1 0/1 1/1 0/1 
23 p.R702C 1 47 1/1 1/1 1/1 1/1 
24 p.R702C 1 20 1/1 1/1 1/1 0/1 
25 p.R702C 1 13 0/1 0/1 0/0 0/1 
26 p.R702C 1 27 1/1 1/1 1/1 1/1 
27 p.R702S 1 44 1/1 0/1 1/1 0/1 
28 p.R702H 2 16 (5-28) 1/2 1/2 2/2 0/2 
29 p.R702H 2 32 (37-28) 1/2 1/2 1/1 0/1 
30 p.R702H 1 26 1/1 1/1 1/1 0/1 
31 p.R702H 2 27 (15-40) 1/2 1/2 2/2 0/2 
32 p.R702H 2 14 (3-25) 1/2 0/2 2/2 0/1 
33 p.R702H 2 26 (1-53) 1/2 1/2 1/2 0/2 
34 p.R718W 1 16 1/1 1/1 0/1 0/1 
35 p.M847_E853dup 2 19 (6-33) 0/2 0/2 0/2 0/2 
36 p.K1048_E1054del 2 27 (10-45) 0/2 0/2 0/2 0/2 
37 p.E1066_A1072del 1 25 0/1 0/1 1/1 1/1 
38 p.E1066_A1072del 2 19 (1-38) 1/2 0/2 1/2 1/2 
39 p.E1066_A1072dup 3 33 (23-51) 0/3 0/3 0/3 1/3 
40 p.T1155A 1 16 0/1 0/1 0/1 0/1 
41 p.T1155I 1 20 (2-46) 2/4 1/4 1/4 1/4 
42 p.R1162T 2 33 (17-50) 0/1 0/2 0/2 0/2 
43 p.R1162T 1 28 0/1 0/1 0/1 0/1 
44 p.R1165C 4 55 (40-76) 0/3 0/4 2/2 1/3 
45 p.R1165C 3 58 (38-82) 0/3 0/3 3/3 0/3 
46 p.R1165C 1 14 0/1 0/1 0/1 0/1 
47 p.R1165C 2 18 (4-33) 1/2 0/2 0/2 0/2 
48 p.R1165C 2 1 0/1 0/1 0/0 0/1 
49 p.R1165C 2 26 (13-40) 0/2 0/2 0/2 1/2 
50 p.R1165C 4 30 (2-60) 0/3 0/4 0/3 1/4 
51 p.R1165C 1 33 0/1 0/1 0/1 0/1 
52 p.R1165L 4 24 (14-37) 3/4 0/4 4/4 1/4 
53 p.R1165L 1 26 0/1 0/1 1/1 0/1 
54 p.D1424H 10 32 (9-63) 2/10 1/10 8/10 6/10 
55 p.D1424H 1 41 1/1 1/1 1/1 1/1 
56 p.D1424H 5 32 (9-45) 4/5 0/5 5/5 2/5 
57 p.D1424H 8 34 (1-56) 5/8 4/8 6/8 2/5 
58 p.D1424H 2 42 (30-54) 2/2 0/2 1/1 1/1 
59 p.D1424H 2 24 (23-25) 0/2 0/2 1/2 0/2 
60 p.D1424H 2 21 (10-32) 1/2 0/2 1/2 1/2 
61 p.D1424H 1 62 1/1 0/1 1/1 1/1 
62 p.D1424H 2 30 (15-46) 0/2 0/2 1/2 0/2 
63 p.D1424N 2 54 (42-67) 0/2 0/2 1/2 0/2 
64 p.D1424N 1 35 0/1 0/1 0/1 0/1 
65 p.D1424N 1 29 0/1 0/1 0/1 0/1 
66 p.D1424N 1 38 0/1 0/1 0/0 0/1 
67 p.D1424N 1 48 0/1 0/1 0/1 0/1 
68 p.D1424N 3 28 (1-59) 0/3 0/3 0/3 0/3 
69 p.D1424N 2 10 (1-21) 0/2 0/2 0/2 0/2 
70 p.D1424N 2 16 (7-26) 0/2 0/2 0/1 0/1 
71 p.D1424Y 1 58 0/1 0/1 1/1 0/0 
72 p.D1424Y 4 50 (34-64) 2/3 0/4 4/4 4/4 
73 p.D1424Y 2 29 (9-49) 0/1 0/2 2/2 0/2 
74  p.D1447Y 1 20 0/1 0/1 0/1 0/1 
75 p.D1447V 4 45 (10-67) 0/4 0/4 3/4 1/4 
76 p.D1447V 1 55 1/1 0/1 1/1 1/1 
77 p.V1516M 3 36 (23-48) 0/3 0/3 0/3 0/3 
78 p.R1557L 2 54 (68-41) 0/2 0/2 1/2 0/2 
79 p.E1841K 5 52 (23-81) 0/5 0/5 2/5 1/5 
80 p.E1841K 4 46 (23-68) 0/4 0/4 0/4 0/4 
81 p.E1841K 1 2 0/1 0/1 0/1 0/1 
82 p.E1841K 2 39 (22-56) 0/2 0/2 1/2 0/2 
83 p.E1841K 1 33 1/1 0/1 1/1 0/1 
84 p.E1841K 2 75 (67-83) 0/2 0/2 1/1 2/2 
85 p.E1841K 1 35 0/1 0/1 0/0 0/0 
86 p.E1841K 5 41 (22-72) 2/5 0/5 2/4 1/4 
87 p.E1841K 1 28 0/1 0/1 0/1 0/1 
88 p.E1841K 1 27 0/1 0/1 0/1 0/1 
89 p.E1841K 1 43 0/1 0/1 0/1 0/1 
90 p.E1841K 1 73 1/1 1/1 1/1 0/1 
91 p.E1841K 7 38 (18-73) 2/7 1/7 5/7 3/7 
92 p.E1841K 1 10 0/1 0/1 0/1 0/1 
93 p.E1841K 1 52 0/1 0/1 0/0 0/0 
94   p.G1924Rfs*21 3 37 (22-46) 0/3 0/3 0/3 0/3 
95   p.D1925Tfs*23 5 29 (2-61) 1/5 1/5 1/5 0/5 
96  p.V1930Cfs*18 4 70 (45-87) 0/4 0/4 2/3 1/4 
97 p.R1933* 5 52 (28-68) 1/5 0/5 1/4 0/4 
98 p.R1933* 4 38 (12-64) 0/4 0/4 0/4 0/4 
99 p.R1933* 2 42 (30-55) 0/2 0/2 0/1 0/0 
100 p.R1933* 2 26 (12-40) 0/2 0/2 0/2 0/0 
101 p.R1933* 1 32 0/1 0/1 0/1 0/1 
102 p.R1933* 3 47 (35-68) 0/3 0/3 1/3 0/3 
103 p.R1933* 2 36 (29-43) 0/2 0/2 1/2 0/1 
104 p.R1933* 1 54 0/1 0/1 1/1 0/1 
105 p.R1933* 2 22 (8-37) 0/2 0/2 0/2 0/1 
106 p.R1933* 3 16 (1-34) 0/3 0/3 1/3 0/3 
107 p.R1933* 2 34 (21-48) 0/2 0/2 0/1 0/2 
108 p.R1933* 3 41 (17-56) 0/3 0/3 2/3 0/3 
109 p.R1933* 1 18 0/1 0/1 0/1 0/1 
110 p.R1933* 1 22 0/1 0/1 0/1 0/1 
111 p.R1933* 2 22 (5-39) 0/2 0/2 0/2 0/2 
112 p.R1933* 1 11 0/1 0/1 0/1 0/1 
113 p.R1933* 2 22 (7-38) 0/2 0/2 0/1 0/1 
114 p.R1933* 1 22 0/0 0/1 0/1 0/1 
115 p.R1933* 2 12 (3-22) 0/2 0/2 0/2 0/2 
116 p.R1933* 4 47 (1-82)   0/4 0/4  2/4 1/4 
117 p.R1933Efs*15 2 37 (25-49) 0/2 0/2 0/2 0/2 
118 p.M1934Wfs*14 2 19 (2-37) 0/2 0/2 1/2 1/2 
119 p.D1941Mfs*7 3 27 (17-42) 1/3 1/3 1/3 0/3 
120 p.D1941Mfs*7 2 32 (17-47) 0/2 0/2 0/2 0/2 
121 p.E1945* 5 28 (2-63) 0/5 0/5 0/5 0/5 
 
Abbreviations: ESRD= end-stage renal disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting Table S2. Clinical presentation of 221 patients with MYH9-RD who were investigated for 
macrothrombocytopenia,  sensorineural deafness, proteinuric nephropathy, and cataract (mean age at 
evaluation, 35 years).  
 
Clinical picture N. of patients (%) Mean age [yrs.]  
Isolated MTCP * 108 (48.9%) 25  
MTCP ** + deafness 40 (18.1%) 41 
MTCP + nephropathy 4 (1.8%) 20 
MTCP + cataracts 3 (1.4%) 27 
MTCP + deafness + nephropathy 30 (13.6%) 33 
MTCP + deafness + cataracts 16 (7.2%) 47 
MTCP + nephropathy + cataracts 1 (0.4%) 2 
MTCP + deafness + nephropathy + cataracts 19 (8.6%) 44 
 
Notes: * in three patients phase-contrast microscopy revealed platelet count at the lower limit of the 
normal range associated with platelet macrocytosis; ** in two patients phase-contrast microscopy revealed 
platelet count at the lower limit of the normal range associated with platelet macrocytosis. 
Abbreviations: MTCP = macrothrombocytopenia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supporting Table S3. Correlations between genotype and platelet count as determined by phase contrast microscopy in 167 MYH9-RD patients.   
 
 
 
N. of 
patients 
 
Median platelet count 
(IQR), x109/L 
 
p value 
 
NMMHC-IIA  
domain 
  
 
Head 35  30  (24-42) p<0.001 
Tail 132    80  (55-100)  
    
NMMHC-IIA  
region 
  
p<0.001 
SH3/MD interface 13  30 (25-48)  p<0.001 vs. coiled-coil and NHT 1 
SH1 helix (R702) 21  27 (24-37) p<0.001 vs. coiled-coil and NHT 1 
Coiled-coil  81  71 (49-95)   
NHT  44   88 (75-102)    
 
Notes: only p ǀĂůƵĞƐч ? ? ? ?ĂƌĞƌĞƉŽƌƚĞĚ ?  1 с Ɖч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supporting Table S4. Correlations between genotype and WHO bleeding score in 183 MYH9-RD patients.   
 
 
 
N. of 
patients 
 
Median platelet 
count, 109/L  (IQR) 
[evaluable patients] 
Median WHO  
bleeding grade (IQR) 
 
p value 
 
% of patients with 
grade 2 / 3 
 
p value 
a
 
 
NMMHC-IIA  
domain 
   
 
 
 
Head 32 27 (21-41) [29] 2  (0.5-3) p<0.001  34 / 28 p<0.001  
Tail 151 80 (55-100) [116] 0  (0-1)  16 / 5     
       
NMMHC-IIA  
region 
   
p<0.001 
 
p<0.001  
SH3/MD interface 13 30 (21-49) [13] 2 (0-3) 
p=0.03 vs. coiled-coil 
and p=0.02 vs. NHT 1 
38 / 31 
p=0.03 vs. coiled-coil 
and p<0.001 vs. NHT 1 
SH1 helix (R702) 18 25 (17-37) [15] 2 (1-3) 
p<0.001 vs. coiled-
coil and NHT 1 
 33 / 28 
p<0.001 vs. coiled-coil 
and NHT 1 
Coiled-coil 84 70 (47-95) [68] 0 (0-1)  13 / 6  
NHT 57 90 (67-102) [39] 0 (0-1)  19 / 2  
 
Notes: only p ǀĂůƵĞƐч ? ? ? ?ĂƌĞƌĞƉŽƌƚĞĚ ?1 сƉч ? ? ? ? ?ƐŝŐŶŝĨŝĐĂŶĐĞĂĨƚĞƌŽŶĨĞƌƌŽŶŝĐŽƌƌĞĐƚŝŽŶ ? 
a
= comparison of the number of patients with WHO grade 0 or 1 vs. WHO grade 2 or 3.   
 
 
